The role of perioperative chemotherapy in the treatment of urothelial cancer

Oncologist

Volumn 11, Issue 6, 2006, Pages 630-640

  Cohen, Seth M ^a,c   Goel, Anupama ^a,c   Phillips, John ^b,c   Ennis, Ronald D ^a,c   Grossbard, Michael L ^a,b,c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c Institute for Head and Neck and Thyroid Cancer   (United States)

Author keywords

Adjuvant; Chemotherapy; Neoadjuvant; Transitional cell carcinoma; Urothelial cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEVER; HUMAN; MUCOSA INFLAMMATION; OTOTOXICITY; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 33745667739     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-6-630     Document Type: Review

References (81)

1. Jemal A, Murray T, Ward E et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
3. Stein JP, Skinner DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am 2005;32:187-197.
4. Herr H, Shipley W, Bajorin D. Cancer of the bladder. In: DeVita V Jr, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology, Sixth Edition. Philadelphia: Lippincott, Williams, and Wilkins, 2001:1396-1415.
5. Shelley MD, Barber J, Wilt T et al. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002;(1):CD002079.
6. Jenkins BJ, Caulfield MJ, Fowler CG et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988;62:343-346.
7. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7:299-310.
8. Parsons JT, Million RR. Planned preoperative irradiation in the management of clinical stage B2-3 (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys 1988;14:797-810.
9. Slack NH, Bross ID, Prout GR Jr. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 1977;9:393-405.
10. Smith JA Jr, Crawford ED, Paradelo JC et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol 1997;157:805-807; discussion 807-808.
11. Huncharek M, Muscat JF, Geschwind J. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res 1998;18:1931-1934.
12. Reisinger SA, Mohiuddin M, Mulholland SG. Combined pre- and postoperative adjuvant radiation therapy for bladder cancer - a ten year experience. Int J Radiat Oncol Biol Phys 1992;24:463-468.
13. Natale RB, Yagoda A, Watson RC et al. Methotrexate: an active drug in bladder cancer. Cancer 1981;47:1246-1250.
14. Blumenreich MS, Yagoda A, Natale RB et al. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 1982;50:435-438.
15. Yagoda A, Watson RC, Whitmore WF et al. Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature. Cancer 1977;39:279-285.
16. Yagoda A, Watson RC, Gonzalez-Vitale JC et al. Cis-dichlorodiamminepla tinum(II) in advanced bladder cancer. Cancer Treat Rep 1976;60:917-923.
17. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-407.
18. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-1073.
19. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-1055.
20. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-2569.
21. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 2001;19:2638-2646.
22. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;22:220-228.
23. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004;100:1639-1645.
24. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
25. Bamias A, Deliveliotis C, Aravantinos G et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group. J Urol 2004;171:1467-1470.
26. von der Maase H, Sengelov L, Roberts J et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608.
27. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:3247-3255.
28. Philips G, Halabi S, Sanford B et al. Phase II trial of cisplatin (C), fixeddose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: preliminary results of CALGB 90102. J Clin Oncol 2004;22(14 suppl):4540.
29. Hussain M, Petrylak D, Dunn R et al. Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: results of a multi-center phase II NCI trial. Presented at the 2005 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 2005, May 13-17, 2005.
30. Rich TA, Skibber JM, Ajani JA et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:1025-1029.
31. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
32. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
33. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1, and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302-306; discussion 306-307.
34. Splinter TA, Scher HI, Denis L et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group. J Urol 1992;147:606-608.
35. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. Proc Am Soc Clin Oncol 1995;14:237..
36. Winquist E, Kirchner TS, Segal R et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and metaanalysis. J Urol 2004;171:561-569.
37. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-1934.
38. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
39. Hall R. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M), and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2002;21:710a.
40. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999;354:533-540.
41. Sternberg CN, Parmar MK. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol 2001;19(18 suppl):21s-6s.
42. Logothetis CJ, Johnson DE, Chong C et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988;6:1590-1596.
43. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine, and methotrexate chemotherapy for muscle-invasive bladder cancer. J Urol 1996;155:495-499; discussion 499-500.
44. Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153:47-52.
45. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-464; discussion 464-467.
46. Bono AV, Benvenuti C, Reali L et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 1989;303:533-540.
47. Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994;152:81-84.
48. Lehmann J, Retz M, Wiemers C et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AOU-AB 05/95). J Clin Oncol 2005;23:4963-4974.
49. Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001;19:4005-4013.
50. Lee CT, Madii R, Daignault S et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 2006;175:1262-1267; discussion 1267.
51. Meliani E, Lapini A, Serni S et al. Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation. Urol Int 2003;71:37-40.
52. Clinical Trials.gov. Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00054626?order=4. Accessed August 5, 2005.
53. Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-2270.
54. Mottet-Auselo N, Bons-Rosset F, Costa P et al. Carboplatin and urothelial tumors. Oncology 1993;50(suppl 2):28-36.
55. Jimenez RE, Gheiler E, Oskanian P et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 2000;24:980-987.
56. Novara G, Ficarra V, Alrabi N et al. Prognostic factors in a recent series of patients treated with radical cystectomy for bladder cancer. Urol Int 2005;75:10-16.
57. Knap MM, Lundbeck F, Overgaard J. Prognostic factors, pattern of recurrence and survival in a Danish bladder cancer cohort treated with radical cystectomy. Acta Oncologia 2003;42:160-168.
58. Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 2003;169:955-960.
59. Thieblemont C, Fendler JP, Trillet-Lenoir V et al. [Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy.] Bull Cancer 1996;83:139-146. French.
60. Lotan Y, Gupta A, Shariat SF et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005;23:6533-6539.
61. Nangia AK, Konety BR, Wachtel S et al. Perineural invasion in transitional cell carcinoma and the effect on prognosis following radical cystectomy. Urology 1997;49:968-972.
62. Fleischmann A, Thalmann G, Markwalder R et al. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005;23:2358-2365.
63. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 1987;60:2766-2774.
64. Herr HW, Bochner BH, Dalbagni G et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002;167:1295-1298.
65. Leissner J, Hohenfellner R, Thuroff JW et al. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000;85:817-823.
66. Herr HW, Faulkner JR, Grossman HB et al. Surgical factors inf luence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004;22:2781-2789.
67. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
68. Serth J, Kuczyk M, Bokemeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995;71:201-205.
69. Sarkis AS, Bajorin DF, Reuter VE et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-1390.
70. Jankevicius F, Goebell P, Kushima M et al. p21 and p53 immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int 2002;69:174-180.
71. ClinicalTrials.gov. Phase III Randomized Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Observation Alone Based on p53 Gene Status in Patients With Organ Confined Transitional Cell Carcinoma of the Bladder Who Have Undergone Radical Cystectomy and Bilateral Pelvic Lymphadenectomy. Available at http://www.clinicaltrials.gov/ct/show/NCT00005047? order=1. Accessed August 5, 2005.
72. Bajorin D, Bochner B, Sandler H et al. Changing paradigms in advanced bladder cancer. In: Perry MC, ed. American Society of Clinical Oncology: Educational Book 2005. Alexandria, VA: Lisa Greaves, 2005:330-350.
73. Madersbacher S, Thalmann GN, Fritsch JC et al. Is eligibility for a chemotherapy protocol a good prognostic factor for invasive bladder cancer after radical cystectomy? J Clin Oncol 2004;22:4103-4108.
74. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer 2002.
75. Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991;67:608-615.
76. Font A, Abad A, Saladie J et al. Improved survival with induction chemotherapy in bladder cancer: preliminary results of a randomized trial. Ann Oncol 1994;5:71.
77. Martinez-Pineiro JA, Gonzalez-Martin M, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995;153:964-973.
78. Malmstrom PU, Rintala E, Wahlqvist R et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155:1903-1906.
79. Bassi P, Pappagallo G, Sperandio P et al. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: results of a multicenter phase III trial. J Urol 1999;161(4 suppl):264.
80. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic Cystectomy Trial 2. Scand J Urol Nephrol 2002;36:419-425.
81. Sengelov L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 2002;41:447-456.